Sponsor:
National Institutes of Health
UI Contact:
Updated Date:
Oct 21, 2022
The National Institutes of Health, through its NIH Guide, has recently published the following funding-related notices and funding opportunities:
Policy Notices
- Notice of Clarification Regarding Data Management Plan Requirement for AHRQ National Research Service Award Institutional Research Training Grant (T32) RFA-HS-22-010
(NOT-HS-23-001)
Agency for Healthcare Research and Quality
General Notices
- Notice of Correction to RFA-CA-22-013, PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24 Clinical Trial Not Allowed)
(NOT-CA-22-136)
National Cancer Institute
- Notice of Pre-Application Webinar and FAQs for the Funding Opportunity Announcement Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) (RFA-CA-22-051)
(NOT-CA-23-008)
National Cancer Institute
- Pre-Application Webinar for NCIs FOAs on Advancing Adolescent Tobacco Cessation Intervention Research (RFA-CA-22-042, RFA-CA-22-43)
(NOT-CA-23-009)
National Cancer Institute
- Notice to Extend the Response Date for NIH Guide NOT-DE-22-019, RFI: Request for Information on Augmenting Research Training and Engaging Scientists in Dental, Oral, and Craniofacial Research Careers
(NOT-DE-22-020)
National Institute of Dental and Craniofacial Research
- Notice of Corrected Application Forms for RFA DE-23-009 Harnessing Technologies to Support Oral Health Promotion and Management Outside the Dental Setting (UG3/UH3 Clinical Trial Required)
(NOT-DE-23-001)
National Institute of Dental and Craniofacial Research
- Clarification of Eligibility for Institutions with Multiple Campuses in PAR-21-169 "Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)"
(NOT-GM-23-006)
National Institute of General Medical Sciences
- Clarification of Eligibility for Institutions with Multiple Campuses in PAR-21-173 "Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)"
(NOT-GM-23-007)
National Institute of General Medical Sciences
- Notice of NICHD Participation in PAR-22-242, "Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)"
(NOT-HD-22-050)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Notice of NICHD Participation in PAR-22-243, "Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)"
(NOT-HD-22-051)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Notice of NICHD Participation in RFA-OD-22-015, "Galvanizing Health Equity Through Novel and Diverse Educational Resources (GENDER) Research Education (R25 Clinical Trial Not Allowed)
(NOT-HD-22-053)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Notice of Frequently Asked Questions (FAQs) for Multi-Omics for Health and Disease RFA-HG-22-008, RFA-HG-22-009, RFA-HG-22-010
(NOT-HG-23-011)
National Human Genome Research Institute
- Notice of Information: Research Opportunity Announcement OTA-20-014-C IMPROVE Community Implementation Program (IMPROVE-CIP) Solicitation for Research Coalitions
(NOT-HL-22-054)
National Heart, Lung, and Blood Institute
- The NIH Office of Disease Prevention (ODP) Announces the Pathways to Prevention Workshop: Identifying Risks and Interventions to Optimize Postpartum Health
(NOT-OD-23-010)
Office of Disease Prevention
- Request for Information (RFI): Soliciting Input on the Use and Reuse of Cancer Metabolomics Data
(NOT-CA-23-007)
National Cancer Institute
Notice of Changes to Funding Opportunities
- Notice to Clarify Eligibility Requirements of Program Directors/Principal Investigators (PDs/PIs) in PAR-21-295 NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)
(NOT-CA-22-137)
National Cancer Institute
- Notice to Clarify Eligibility Requirements of Program Directors/Principal Investigators (PDs/PIs) in PAR-21-300 NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Independent Clinical Trial Not Allowed)
(NOT-CA-22-140)
National Cancer Institute
- Notice of Correction of Key Dates in RFA-CA-22-042, Advancing Adolescent Tobacco Cessation Intervention Research (R34 Clinical Trial Optional)
(NOT-CA-23-003)
National Cancer Institute
- Notice of Change to The Page Limits for RFA-HG-22-027, "Diversity Centers for Genome Research (UG3/UH3 Clinical Trials Optional)"
(NOT-HG-23-010)
National Human Genome Research Institute
Notices of Intent to Publish
- Notice of Intent to Publish a Funding Opportunity Announcement for the National Institute on Aging (NIA) Alzheimer's Disease (AD) and Alzheimer's Disease-Related Dementias (ADRD) Real-World Data (RWD) Platform Initiative (U54 Clinical Trial Required)
(NOT-AG-22-044)
National Institute on Aging
Notices of Special Interest
- Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers
(NOT-CA-23-004)
National Cancer Institute
- Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NIDA Populations of Interest
(NOT-DA-22-084)
National Institute on Drug Abuse
Funding Opportunities
- Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
(PAR-23-021)
National Institute on Drug Abuse
- NCMRR Early Career Research Award (R03 Clinical Trial Optional)
(PAR-23-029)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Research Networks to Promote Multidisciplinary Mechanistic Studies on Music-Based Interventions for Pain or Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD) (U24 Clinical Trial Optional)
(RFA-AT-23-006)
National Center for Complementary and Integrative Health
National Institute on Aging
- Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)
(RFA-DA-24-007)
National Institute on Drug Abuse
- Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
(RFA-DK-22-039)
National Institute of Diabetes and Digestive and Kidney Diseases
- Utilizing Telomere Status to Reveal Molecular Mechanisms Underlying Susceptibility and Resiliency in Response to Environmental Exposures (R01 Clinical Trial Not Allowed)
(RFA-ES-22-007)
National Institute of Environmental Health Sciences
Members of the University of Iowa community may direct questions to the UI Division of Sponsored Programs at dsp@uiowa.edu(link sends e-mail) or 313-335-2123, or email Ann Ricketts at ann-ricketts@uiowa.edu(link sends e-mail) or Lynn Hudachek at lynn-hudachek@uiowa.edu(link sends e-mail).